Treatment of Hot Flashes
For moderate to severe hot flashes in otherwise healthy adults, start with SSRIs/SNRIs (particularly venlafaxine or paroxetine), gabapentin, or pregabalin as first-line pharmacological options, with the understanding that menopausal hormone therapy (MHT) remains more effective if not contraindicated. 1
Treatment Algorithm
First-Line Pharmacological Options (Non-Hormonal)
The Endocrine Society guidelines strongly recommend the following agents for moderate to severe vasomotor symptoms when hormone therapy is contraindicated or declined 1:
SSRIs/SNRIs:
- Venlafaxine 75-150 mg daily - Reduces hot flashes by approximately 60-70% (vs 30% placebo effect)
- Paroxetine 7.5-25 mg daily - The only FDA-approved agent in this class; reduces frequency by up to 69%
- Desvenlafaxine 100-150 mg daily - Similar efficacy to venlafaxine
- Citalopram 10-20 mg daily or Escitalopram 10-20 mg daily - Statistically significant but slightly less robust data
Critical caveat: Avoid paroxetine in patients taking tamoxifen, as it significantly interferes with tamoxifen metabolism to its active metabolite endoxifen 1
Gabapentin/Pregabalin:
- Gabapentin 900-2400 mg daily (typically 300-1200 mg at bedtime for nocturnal symptoms) - Reduces hot flashes moderately; particularly effective for nighttime symptoms due to sedative properties 1
- Pregabalin 75-150 mg twice daily - Decreased hot flash scores by 65-71% vs 50% placebo 1
Head-to-head comparison: Venlafaxine and gabapentin showed equivalent 66% reduction in hot flash scores, but two-thirds of patients preferred venlafaxine over gabapentin, likely due to better tolerability 1
Second-Line Option
Clonidine (transdermal preferred) - Use only if patients fail or cannot tolerate SSRIs/SNRIs, gabapentin, or pregabalin. Less effective than first-line agents with more side effects (dry mouth, postural hypotension, fatigue, constipation) 1, 2
Hormone Therapy Context
While this question asks about an "otherwise healthy adult," it's critical to note that standard-dose MHT reduces hot flashes by 70-80% and remains more effective than all non-hormonal agents 1. Limited head-to-head trials suggest MHT superiority, though non-hormonal options reduce symptoms by 25-69% and are approximately half as effective as estrogen 3, 4.
Important Safety Considerations
SSRIs/SNRIs contraindications:
- Prior neuroleptic or serotonin syndrome
- Concurrent MAO inhibitor use
- Use cautiously in bipolar disease, uncontrolled seizures, hepatic/renal insufficiency
- Monitor for suicidal ideation in first few months
- Preliminary evidence suggests possible increased bone fracture risk 1
Gabapentin/Pregabalin warnings:
- May increase suicidal thoughts and behaviors
- Cause drowsiness, dizziness, impaired balance/coordination
- Pregabalin may impair memory and concentration
- Gabapentin's daytime sedation often limits tolerability 1
Lifestyle Modifications
For mild symptoms, consider environmental modifications first: fans, air conditioning, light cotton clothing, and maintaining cool environments 2. However, exercise, relaxation, and paced respiration have no proven benefit for hot flash reduction 3.
The Placebo Effect Pitfall
A critical consideration when counseling patients: hot flash studies consistently show a 30% placebo response (range 4-57%), occurring more frequently in women with high anxiety and stress 1. This substantial placebo effect makes interpreting treatment efficacy challenging and underscores the importance of setting realistic expectations.
Practical Prescribing Approach
- Start with venlafaxine 75 mg daily or gabapentin 300 mg at bedtime (if nocturnal symptoms predominate)
- Titrate based on response and tolerability over 2-4 weeks
- If inadequate response, switch to alternative first-line agent rather than adding therapies
- Reserve clonidine for treatment-refractory cases
- Reassess need for continued therapy periodically, as symptoms may resolve spontaneously over time